BioWorld

Oct. 29, 2002

Dendreon Gets OK To Resume Enrollment In Phase III Study

Following a six-month delay, Dendreon Corp. received FDA clearance to resume enrollment in its second Phase III trial of Provenge, a therapeutic vaccine for hormone-resistant prostate cancer patients. (BioWorld Today) Read More

Peninsula Raises $22.1M To Fund In-Licensing Program

NIH Scientists Report Finding New Deafness Gene, Mucolipin By Name, Joining Worldwide Panoply Of Same

Abbott's Humira Continues To Impress In RA Treatment

Other News To Note

Correction

Endo's Second Phase III For MorphiDex Misses Endpoint

Aphton Reports Phase III Results Showing G17DT Extends Survival

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...

HMNC raises $50M series B to prep depression drugs for phase III

BioWorld

HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...